Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group.
chemotherapy
epithelial ovarian cancer
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 Mar 2021
04 Mar 2021
Historique:
received:
25
01
2021
revised:
16
02
2021
accepted:
26
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36-56). The median OS was 77.2 months (65.9-106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months,
Identifiants
pubmed: 33806443
pii: jcm10051058
doi: 10.3390/jcm10051058
pmc: PMC7961531
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 2015 Jun;137(3):401-5
pubmed: 25839911
J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):369-378
pubmed: 30936027
Gynecol Oncol. 2016 Nov;143(2):241-245
pubmed: 27615398
Eur J Cancer. 2013 Jan;49(1):142-9
pubmed: 22921185
AJR Am J Roentgenol. 2016 Jun;206(6):1351-60
pubmed: 27042752
Gynecol Oncol. 2013 Oct;131(1):15-20
pubmed: 23877013
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Natl Cancer Inst Monogr. 1975 Oct;42:101-4
pubmed: 1234624
Int J Gynecol Cancer. 2017 Feb;27(2):274-280
pubmed: 28114235
Obstet Gynecol. 2012 Oct;120(4):871-81
pubmed: 22996105
Gynecol Oncol. 2016 Dec;143(3):484-489
pubmed: 27726923
Int J Gynecol Cancer. 2016 Sep;26(7):1354-63
pubmed: 27648648
Int J Surg Oncol. 2010;2010:214919
pubmed: 22312486
Gynecol Oncol. 2002 Sep;86(3):354-7
pubmed: 12217760
Gynecol Oncol. 2016 Jun;141(3):466-470
pubmed: 27098361
Eur J Surg Oncol. 2006 Jun;32(5):588-91
pubmed: 16569491
Int J Gynecol Cancer. 2018 Oct;28(8):1520-1528
pubmed: 30036229
Ann Oncol. 2016 Jan;27(1):114-21
pubmed: 26487588
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
N Engl J Med. 2004 Dec 9;351(24):2519-29
pubmed: 15590954
Int J Gynaecol Obstet. 2018 Dec;143(3):325-332
pubmed: 30129040
Br J Cancer. 2008 Apr 8;98(7):1197-203
pubmed: 18349836
J Natl Cancer Inst. 2006 Feb 1;98(3):163-71
pubmed: 16449676
Gynecol Oncol. 2017 Feb;144(2):260-265
pubmed: 27908531
J Natl Cancer Inst. 2006 Feb 1;98(3):172-80
pubmed: 16449677